Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant acquires Amarin’s U.S. drug company

Executive Summary

Valeant to acquire Amarin's U.S. pharmaceutical business for $46 mil. The purchase will expand Valeant's CNS business (which includes Mestinon for myasthenia gravis) by adding Amarin's Parkinson's therapies Permax (pergolide) and Zelapar (rapid-dissolving selegiline), which is "approvable" at FDA. Amarin retains exclusive U.S. rights to LAX-101, in Phase III for Huntington's Disease. The Valeant deal will help cover Amarin's outstanding financial obligations of $24.4 mil. to Elan regarding Zelapar (1"The Pink Sheet" Aug. 6, 2001, p. 36)...

You may also be interested in...

Amarin/Elan Parkinson's deal

Amarin plans to file an NDA for rapid-dissolving selegiline formulation Zelapar in the first half of 2002 following the acquisition from Elan of U.S. rights to the Parkinson's treatment. London-based Amarin (formerly Ethical Holdings) will also promote the Parkinson's therapy Permax (pergolide) with 24 reps; the product generated sales of $40 mil. in 2000

Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint

Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.

Global Medtech Guidance Tracker: September 2020

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts